Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Cash from Investing Activities: 2015-2025

Historic Cash from Investing Activities for Intellia Therapeutics (NTLA) over the last 11 years, with Sep 2025 value amounting to -$741,000.

  • Intellia Therapeutics' Cash from Investing Activities rose 90.39% to -$741,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $352.1 million, marking a year-over-year increase of 1665.52%. This contributed to the annual value of $125.6 million for FY2024, which is 500.57% up from last year.
  • As of Q3 2025, Intellia Therapeutics' Cash from Investing Activities stood at -$741,000, which was down 100.69% from $106.9 million recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' Cash from Investing Activities ranged from a high of $151.6 million in Q4 2024 and a low of -$399.4 million during Q3 2021.
  • For the 3-year period, Intellia Therapeutics' Cash from Investing Activities averaged around $26.8 million, with its median value being $5.9 million (2024).
  • In the last 5 years, Intellia Therapeutics' Cash from Investing Activities slumped by 357.51% in 2023 and then surged by 1,498.51% in 2025.
  • Over the past 5 years, Intellia Therapeutics' Cash from Investing Activities (Quarterly) stood at -$159.1 million in 2021, then soared by 81.05% to -$30.2 million in 2022, then spiked by 252.36% to $45.9 million in 2023, then spiked by 229.93% to $151.6 million in 2024, then surged by 90.39% to -$741,000 in 2025.
  • Its Cash from Investing Activities stands at -$741,000 for Q3 2025, versus $106.9 million for Q2 2025 and $94.3 million for Q1 2025.